¾ÅÖÝÓ°Ôº

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information

The FDA’s final Medical Device Data System (MDDS) rule and its implications for currently regulated and unregulated vendors and providers

28 April 2011, Palo Alto, United States


Introduction
The FDA signaled a shift from regulatory discretion to enforcement discretion regarding Medical Device Data Systems (MDDS) with the publishing of the final rule on February 14, 2011. Ostensibly, the FDA reclassified these systems from Class III to Class I. But the most remarkable consequence from the final rule is naming of specific entities that may be subject to potential FDA enforcement actions.

The rapid adoption of Electronic Medical Records, advent of Meaningful Use and subsequent desire to automatically acquire medical device data for inclusion in electronic records has resulted in the development and adoption of Medical Device Data Systems. FDA has observed the evolution of this market for some years, and the agency's mandate to ensure patient safety has motivated it to publish this final rule.

This webinar will compare and contrast the proposed and final rule, and discuss what systems and products meet the definition of a MDDS. The named entities that may be subject to enforcement will be discussed, including the FDA's rationale for enforcement authority. Effective compliance dates and required actions will be presented.

Useful links

Venue
Online Event

Online Event, 2600 E. Bayshore Road, Palo Alto, 94303, United States

Useful links

Organised by
ComplianceOnline
Contact information
Mr Ryan
2600 E. Bayshore Road, Palo Alto, 94303, United States of America
+1-650-620-3915
Contact us by email

Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*